dalteparin has been researched along with Hip Fractures in 39 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Hip Fractures: Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe." | 9.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| "To compare the efficacy and safety of aspirin with rivaroxaban following treatment with enoxaparin for prevention of venous thromboembolism (VTE) after hip fracture surgery (HFS)." | 7.91 | Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery. ( Huang, Q; Shen, B; Si, HB; Xing, SX; Zeng, Y; Zhou, ZK, 2019) |
| "The selective antithrombotic fondaparinux is more effective than the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism (deep-vein thrombosis [DVT] or pulmonary embolism) in patients undergoing major orthopedic surgery, but its cost-effectiveness is undetermined." | 7.72 | The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. ( Borris, L; Bossuyt, P; de Pouvourville, G; Gordois, A; Jönsson, B; Levy, E; Posnett, J, 2003) |
| "The aim of the EXTEND study was to assess safety and efficacy of extended administration (35 days) of ximelagatran or enoxaparin for the prevention of venous thromboembolism after elective hip replacement and hip fracture surgery." | 5.14 | Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. ( Agnelli, G; Andersson, M; Bergqvist, D; Boberg, B; Bylock, A; Cohen, AT; Dahl, OE; Eriksson, BI; Jensen, E; Lassen, MR; Mouret, P; Rosencher, N, 2009) |
| "In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe." | 5.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| " The incidence of VTE and hematoma formation was evaluated and compared between patients who received aspirin versus enoxaparin or heparin." | 4.12 | Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures? ( Du, JY; Metcalf, KB; Ochenjele, G, 2022) |
| "To compare the efficacy and safety of aspirin with rivaroxaban following treatment with enoxaparin for prevention of venous thromboembolism (VTE) after hip fracture surgery (HFS)." | 3.91 | Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery. ( Huang, Q; Shen, B; Si, HB; Xing, SX; Zeng, Y; Zhou, ZK, 2019) |
| "The selective antithrombotic fondaparinux is more effective than the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism (deep-vein thrombosis [DVT] or pulmonary embolism) in patients undergoing major orthopedic surgery, but its cost-effectiveness is undetermined." | 3.72 | The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. ( Borris, L; Bossuyt, P; de Pouvourville, G; Gordois, A; Jönsson, B; Levy, E; Posnett, J, 2003) |
| "Edoxaban is an oral, direct, once-daily factor Xa inhibitor." | 2.79 | Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. ( Abe, K; Fuji, T; Fujita, S; Kawai, Y; Kimura, T; Kiuchi, Y; Nakamura, M; Tachibana, S, 2014) |
| " The purpose of this study was to assess the impact of the route of administration and dosage regimen on the compliance to the prescription." | 1.56 | Extended thromboprophylaxis for hip or knee arthroplasty. Does the administration route and dosage regimen affect adherence? A cohort study. ( Bautista, M; Bonilla, G; Castro, J; Llinás, A; Moreno, JP, 2020) |
| "To evaluate the rates of deep vein thrombosis (DVT) and pulmonary embolism (PE) in hip fracture patients receiving mechanical thromboprophylaxis." | 1.36 | Mechanical thromboprophylaxis for patients undergoing hip fracture surgery. ( Lee, HC; Loh, JS; Mehta, KV, 2010) |
| "Fondaparinux sodium is a new antithrombotic agent that is indicated for prophylaxis of VTE after major orthopedic surgery." | 1.33 | Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis. ( Bjorvatn, A; Kristiansen, F, 2005) |
| " The rates of minor bleeding complications in the aspirin group, the < 12-hour postoperative dosing of the enoxaparin group, and the 12 to 24-hour postoperative dosing of the enoxaparin group were 3." | 1.32 | Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting. ( Ennis, RS, 2003) |
| " Incremental cost-effectiveness ratio calculations demonstrate that warfarin dosed to an international normalized ratio of 2-2." | 1.31 | Cost effectiveness of deep venous thrombosis prophylaxis after hip fracture. ( Chisholm, MA; Wade, WE, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.13) | 18.2507 |
| 2000's | 18 (46.15) | 29.6817 |
| 2010's | 13 (33.33) | 24.3611 |
| 2020's | 6 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Haentjens, P | 1 |
| San Juan Alvarez, M | 1 |
| Márquez Garrido, G | 1 |
| Rodríguez Bertos, C | 1 |
| González Pérez, L | 1 |
| Abatzis-Papadopoulos, M | 1 |
| Tigkiropoulos, K | 1 |
| Nikas, S | 1 |
| Papoutsis, I | 1 |
| Kostopoulou, O | 1 |
| Stavridis, K | 1 |
| Karamanos, D | 1 |
| Lazaridis, I | 1 |
| Saratzis, N | 1 |
| Metcalf, KB | 1 |
| Du, JY | 1 |
| Ochenjele, G | 1 |
| Joo, PY | 1 |
| Modrak, M | 1 |
| Park, N | 1 |
| Brand, J | 1 |
| Rubin, LE | 1 |
| Grauer, JN | 1 |
| Bernstein, JA | 1 |
| Sivro, M | 1 |
| Omerović, Đ | 1 |
| Lazović, F | 1 |
| Papović, A | 1 |
| Huang, Q | 1 |
| Xing, SX | 1 |
| Zeng, Y | 1 |
| Si, HB | 1 |
| Zhou, ZK | 1 |
| Shen, B | 1 |
| Moreno, JP | 1 |
| Bautista, M | 1 |
| Castro, J | 1 |
| Bonilla, G | 1 |
| Llinás, A | 1 |
| Mula, V | 1 |
| Parikh, S | 1 |
| Suresh, S | 1 |
| Bottle, A | 1 |
| Loeffler, M | 1 |
| Alam, M | 1 |
| Tang, Y | 1 |
| Wang, K | 1 |
| Shi, Z | 1 |
| Yang, P | 1 |
| Dang, X | 1 |
| Campbell, ST | 1 |
| Bala, A | 1 |
| Jiang, SY | 1 |
| Gardner, MJ | 1 |
| Bishop, JA | 1 |
| Zhang, Z | 1 |
| Li, Z | 1 |
| Li, J | 1 |
| Liu, L | 1 |
| Feldinger, LE | 1 |
| Fuji, T | 1 |
| Fujita, S | 1 |
| Kawai, Y | 1 |
| Nakamura, M | 1 |
| Kimura, T | 1 |
| Kiuchi, Y | 1 |
| Abe, K | 1 |
| Tachibana, S | 1 |
| Comp, P | 1 |
| Happe, LE | 1 |
| Sarnes, M | 1 |
| Farrelly, E | 1 |
| Granero Xiberta, J | 1 |
| Soler Minoves, JM | 1 |
| Garcia Nuño, L | 1 |
| Knesek, MJ | 1 |
| Litinas, E | 1 |
| Adiguzel, C | 1 |
| Hopkinson, W | 1 |
| Hoppensteadt, D | 1 |
| Lassen, M | 1 |
| Fareed, J | 1 |
| Oztürk, A | 1 |
| Ozkan, Y | 1 |
| Akgöz, S | 1 |
| Yalçin, N | 1 |
| Aykut, S | 1 |
| Ozdemir, MR | 1 |
| Mehta, KV | 1 |
| Lee, HC | 1 |
| Loh, JS | 1 |
| Willard, RN | 1 |
| Muñiz, AE | 1 |
| Chuidian, F | 1 |
| Lassen, MR | 5 |
| Fisher, W | 1 |
| Mouret, P | 3 |
| Agnelli, G | 3 |
| George, D | 1 |
| Kakkar, A | 1 |
| Mismetti, P | 2 |
| Turpie, AG | 4 |
| Bauer, KA | 2 |
| Eriksson, BI | 5 |
| Ennis, RS | 1 |
| Gordois, A | 1 |
| Posnett, J | 1 |
| Borris, L | 1 |
| Bossuyt, P | 1 |
| Jönsson, B | 1 |
| Levy, E | 1 |
| de Pouvourville, G | 1 |
| Sullivan, SD | 1 |
| Davidson, BL | 1 |
| Kahn, SR | 2 |
| Muntz, JE | 1 |
| Oster, G | 1 |
| Raskob, G | 1 |
| DeWitt, E | 1 |
| Adams, J | 1 |
| Bostwick, C | 1 |
| O'Dell, M | 1 |
| Bjorvatn, A | 1 |
| Kristiansen, F | 1 |
| Schiff, RL | 1 |
| Shrier, I | 1 |
| Strulovitch, C | 1 |
| Hammouda, W | 1 |
| Cohen, E | 1 |
| Zukor, D | 1 |
| Jeong, GK | 1 |
| Gruson, KI | 1 |
| Egol, KA | 1 |
| Aharonoff, GB | 1 |
| Karp, AH | 1 |
| Zuckerman, JD | 1 |
| Koval, KJ | 1 |
| Cohen, AT | 1 |
| Bergqvist, D | 1 |
| Dahl, OE | 1 |
| Rosencher, N | 1 |
| Andersson, M | 1 |
| Bylock, A | 1 |
| Jensen, E | 1 |
| Boberg, B | 1 |
| Finsen, V | 2 |
| Murashige, N | 1 |
| Kami, M | 1 |
| Tvito, A | 1 |
| Bakchoul, T | 1 |
| Rowe, JM | 1 |
| Greinacher, A | 1 |
| Ganzel, C | 1 |
| Magnusson, M | 1 |
| Kälebo, P | 1 |
| Sivertsson, R | 1 |
| Wade, WE | 1 |
| Chisholm, MA | 1 |
| Fisher, WD | 1 |
| George, DJ | 1 |
| Kakkar, AK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Open Label, Safety and Efficacy Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery (STARS J-4 Trial)[NCT01181141] | Phase 3 | 92 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery[NCT00697099] | Phase 3 | 2,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery[NCT00721760] | Phase 3 | 1,003 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of Semuloparin (AVE5026) With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery[NCT00718224] | Phase 3 | 1,150 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| "The EXTEND Study: A Randomized, Double-blind, Parallel-group, Phase III b, Multi-centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergo[NCT00206089] | Phase 3 | 3,300 participants | Interventional | 2005-09-30 | Terminated (stopped due to Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety.) | ||
| The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients[NCT00531843] | Phase 2/Phase 3 | 105 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Placebo for the Extended Prevention of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery[NCT00709904] | Phase 3 | 469 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bleeding events during the period from the start of treatment with the study drug (study treatment) to the day of the follow-up examination were assessed as the primary endpoints. (NCT01181141)
Timeframe: 2 weeks
| Intervention | percentage of subjects with bleeds (Number) |
|---|---|
| DU-176b | 3.4 |
| Enoxaparin Sodium | 6.9 |
Coagulopathic bleeding due to fondaparinux was suspected in patients requiring packed red cell transfusions after initiation of fondaparinux therapy only if the change in hematocrit prompting transfusion was not clinically commensurate with the degree of injuries that the patient had sustained (primarily orthopaedic) and/or the hematocrit did not respond appropriately post-transfusion. (NCT00531843)
Timeframe: 3 weeks post injury
| Intervention | participants (Number) |
|---|---|
| Fondaparinux Sodium | 0 |
Serum samples were collected 30 minutes before (trough) and 2 hours after (peak) the third dose of fondaparinux. Normative data plots comparing study participants with healthy volunteers were supplied by the company outsourced to analyze samples. (NCT00531843)
Timeframe: Day 3
| Intervention | Participants (Number) | |
|---|---|---|
| Trough values outside normative range | Peak values outside normative range | |
| Fondaparinux Sodium | 0 | 0 |
Color-flow duplex venous ultrasonography examinations of upper and lower extremities were performed within 48 hours of injury, and then weekly until discharge or 3 weeks. DVT was defined as any clot occurring in the subclavian, iliac, femoral, or popliteal location. Patients were examined daily for clinical signs and symptoms of venous thromboembolism (VTE) and PE. Small, nonocclusive clots discovered in other locations were observed for progression on sequential ultrasonography examinations. (NCT00531843)
Timeframe: within 3 weeks post injury
| Intervention | participants (Number) | ||
|---|---|---|---|
| DVT | DVT after fondaparinux | PE | |
| Fondaparinux Sodium | 2 | 1 | 0 |
| No Fondaparinux | 2 | NA | 0 |
3 reviews available for dalteparin and Hip Fractures
| Article | Year |
|---|---|
The effectiveness and safety of direct oral anticoagulants compared to conventional pharmacologic thromboprophylaxis in hip fracture patients: A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Random | 2023 |
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Confidence In | 2002 |
Improvements in the prevention of postoperative venous thromboembolism in hip fracture patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials, Phase III | 2003 |
8 trials available for dalteparin and Hip Fractures
| Article | Year |
|---|---|
Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium)
Topics: Aged; Anticoagulants; Drug Administration Schedule; Female; Hip Fractures; Humans; Leg Injuries; Mal | 1996 |
A RCT study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture.
Topics: Aged; Aged, 80 and over; China; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Sche | 2017 |
Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
Topics: Aged; Blood Loss, Surgical; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; | 2014 |
Inflammatory biomarker profiling in elderly patients with acute hip fracture treated with heparins.
Topics: Acute Disease; Acute-Phase Proteins; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacem | 2010 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticoagulants; Arthroplasty, Replacement, Hip | 2009 |
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Topics: Aged; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Hip Fr | 2001 |
Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Fibrinolytic Agents; Hepari | 2013 |
28 other studies available for dalteparin and Hip Fractures
| Article | Year |
|---|---|
[Hip fracture during pregancy in a woman with transient osteporosis].
Topics: Accidental Falls; Adult; Anticoagulants; Bone Screws; Cesarean Section; Female; Fracture Fixation, I | 2010 |
Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures?
Topics: Anticoagulants; Aspirin; Chemoprevention; Enoxaparin; Hematoma; Heparin; Hip Fractures; Humans; Pelv | 2022 |
Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study.
Topics: Anticoagulants; Enoxaparin; Hip Fractures; Humans; Venous Thromboembolism; Warfarin | 2022 |
The effects of three different low-molecular-weight heparins on blood loss after intramedullary nailing of trochanteric fractures.
Topics: Anticoagulants; Blood Loss, Surgical; Bone Nails; Dalteparin; Enoxaparin; Fracture Fixation, Intrame | 2023 |
Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Ther | 2019 |
Extended thromboprophylaxis for hip or knee arthroplasty. Does the administration route and dosage regimen affect adherence? A cohort study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Repl | 2020 |
Venous thromboembolism rates after hip and knee arthroplasty and hip fractures.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2020 |
Are factor Xa inhibitors effective thromboprophylaxis following hip fracture surgery?: A large national database study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Databases, Factual; Enoxapa | 2017 |
Effects of Natural Hirudin and Low Molecular Weight Heparin in Preventing Deep Venous Thrombosis in Aged Patients with Intertrochanteric Fracture.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Hip Fractures; Hir | 2018 |
Recurrent and consistent improvement of cognitive impairment and depression after short time of treatment with enoxaparin.
Topics: Accidental Falls; Aged, 80 and over; Anticoagulants; Cognition Disorders; Depression; Enoxaparin; Hi | 2013 |
Venous thromboembolism clinically detected after hip fracture surgery with prophylaxis in a clinical practice setting.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Cohort Studies; Dalteparin; Enoxapari | 2008 |
[Thromboembolic disease in orthopedic surgery].
Topics: Anesthesia, Conduction; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Early Ambul | 2008 |
The effect of blood albumin and total lymphocyte count on short-term results in elderly patients with hip fractures.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Hip Fractures; Humans; Lymphocyte Count | 2009 |
Mechanical thromboprophylaxis for patients undergoing hip fracture surgery.
Topics: Aged; Aged, 80 and over; Cohort Studies; Enoxaparin; Female; Fibrinolytic Agents; Fracture Fixation; | 2010 |
Delayed subdural hematoma after receiving enoxaparin for prevention of thromboembolic events from high-risk surgery.
Topics: Aged; Emergency Service, Hospital; Enoxaparin; Fibrinolytic Agents; Hematoma, Subdural, Acute; Hip F | 2012 |
Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Enoxaparin; Female; Frac | 2003 |
The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort Studies; Cos | 2003 |
A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery.
Topics: Aged; Aged, 80 and over; Anticoagulants; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Anal | 2004 |
Gastrointestinal bleeding in an elderly patient with a recent hip replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Contraindications; Diagnosi | 2004 |
Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit | 2005 |
Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.
Topics: Adult; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2005 |
Thromboprophylaxis after hip fracture: evaluation of 3 pharmacologic agents.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dextrans; Enoxaparin; Female; Fibrinolytic Agents; | 2007 |
[Thrombosis prophylaxis in orthopedic surgery].
Topics: Dalteparin; Dextrans; Enoxaparin; Femoral Fractures; Fibrinolytic Agents; Heparin, Low-Molecular-Wei | 2000 |
Duration of thrombosis prophylaxis in orthopaedic surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Hip Fractu | 2001 |
Prevention of venous thromboembolism with fondaparinux.
Topics: Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hip Fractures; Humans; | 2002 |
Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment.
Topics: Aged, 80 and over; Antibodies; Anticoagulants; Blood Platelets; Dalteparin; Female; Fondaparinux; Hi | 2015 |
Is colour Doppler ultrasound a sensitive screening method in diagnosing deep vein thrombosis after hip surgery?
Topics: Anticoagulants; Dalteparin; Dextrans; Hip Fractures; Hip Prosthesis; Hirudin Therapy; Hirudins; Huma | 1996 |
Cost effectiveness of deep venous thrombosis prophylaxis after hip fracture.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Hip Fractures; Humans; Leg; Postoperative Complic | 2000 |